New study tracks safety of growth hormone drug in indian children

NCT ID NCT06587035

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times

Summary

This study is checking the safety of a medicine called Somatrogon for children with growth hormone deficiency (short stature) in India. About 50 children aged 3 and older who are already prescribed Somatrogon will be followed for up to 3 years. Doctors will record any side effects, and follow-ups can happen by phone or clinic visit. The goal is to see how safe the drug is in real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DWARFISM, PITUITARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Apollo Children's Hospital
RECRUITING

Chennai, Tamil Nadu, 600006, India
Apollo Speciality Hospital
RECRUITING

Madurai, Tamil Nadu, 625020, India
G Kuppuswamy Naidu Memorial Hospital
RECRUITING

Coimbatore, Tamil Nadu, 641037, India
Shivajoyti Clinic
RECRUITING

Bengaluru, Karnataka, 560008, India

Conditions

Explore the condition pages connected to this study.

DWARFISM, PITUITARY